Background: Hypertension is the most important public health problem in developing countries. Globally, its prevalence is rising making it as one of the major risk factors for cardiovascular diseases, and it has been reported that hypertension is in part an inflammatory disorder. Inflammatory markers, such as interleukin–1 (IL–1) and IL–6, have less clinical utility because the assays, required for their assessment, are either inappropriate for routine clinical use or the protein of interest has too short a half–life for clinical evaluation. The novel cardiac risk assessment tool, hs–CRP is gaining more recognition as a biomarker. Aim:The main aim of the present study was to evaluate the association between blood pressure and serum Hs– CRP levels among patients with hypertension and prehypertension and their comparison with normotensive controls. Material and method: A total of 30 hypertensives, 30 pre–hypertensives and 30 age and sex matched healthy control subjects were selected for the study, with consent. BP readings were taken on both arms, with a mercury sphygmomanometer. The estimation of serum hsCRP was done. Result: Comparison of hs–CRP levels between hypertensive patients and normotensive control subjects and between patient groups with hypertension and prehypertension were statistically significant. Conclusion:Thus, by knowing the relationship between serum hs–CRP and blood pressure early prevention and control can be achieved and will help to avoid or delay the grave outcome and complications of hypertension.